Oral Paclitaxel Provides Infusion-Free Alternative in MBC

Originally published by our sister publication Clinical Oncology NewsBy Jennifer KulpaWeekly paclitaxel is a common first-line option in HER2-negative metastatic breast cancer (mBC), but it requires frequent infusions, and its use can be limited by cumulative neuropathy and infusion-related reactions. In the OPTIMAL phase 3 trial, an oral paclitaxel formulation, DHP107, achieved disease control similar to weekly IV paclitaxel with lower rates of peripheral neuropathy and hypersensitivity reactio